STAT3 and plasma cell myeloma: In multiple myeloma-derived BMMSCs, it has recently been reported that miR-21 directly targeted to reduce OPG and indirectly promoted RANKL by targeting the signal transducer and activator of transcription 3 (STAT3) pathway, suggesting inhibition of osteoclastogenesis by miR-2110.